These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29952857)

  • 1. Sorafenib for Treatment of Hepatocellular Carcinoma: A Survival Analysis From the South American Liver Research Network.
    Leathers JS; Balderramo D; Prieto J; Diehl F; Gonzalez-Ballerga E; Ferreiro MR; Carrera E; Barreyro F; Diaz-Ferrer J; Singh D; Mattos AZ; Carrilho F; Debes JD
    J Clin Gastroenterol; 2019 Jul; 53(6):464-469. PubMed ID: 29952857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
    Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
    World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib.
    da Fonseca LG; Marta GN; Braghiroli MIFM; Chagas AL; Carrilho FJ; Hoff PM; Sabbaga J
    BMC Cancer; 2018 Dec; 18(1):1250. PubMed ID: 30545331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
    J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
    Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
    World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Xu L; Gao H; Huang J; Wang H; Zhou Z; Zhang Y; Li S; Chen M
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1032-9. PubMed ID: 25639513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study.
    Fu SR; Zhang YQ; Li Y; Hu BS; He X; Huang JW; Zhan MX; Lu LG; Li JP
    Asian Pac J Cancer Prev; 2014; 15(7):3151-6. PubMed ID: 24815462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
    Abdel-Rahman O; Abdelwahab M; Shaker M; Abdelwahab S; Elbassiony M; Ellithy M
    J Egypt Natl Canc Inst; 2014 Mar; 26(1):9-13. PubMed ID: 24565677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Pinter M; Sieghart W; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Matejka J; Stauber R; Buder R; Grünberger B; Schöniger-Hekele M; Müller C; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2011 Oct; 34(8):949-59. PubMed ID: 21883324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.
    Yang H; Woo HY; Lee SK; Han JW; Jang B; Nam HC; Lee HL; Lee SW; Song DS; Song MJ; Oh JS; Chun HJ; Jang JW; Lozada A; Bae SH; Choi JY; Yoon SK
    Clin Mol Hepatol; 2017 Jun; 23(2):128-137. PubMed ID: 28494528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.
    Lee SW; Lee TY; Peng YC; Yang SS; Yeh HZ; Chang CS
    Medicine (Baltimore); 2019 Nov; 98(44):e17692. PubMed ID: 31689794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib.
    Ha Y; Mohamed Ali MA; Petersen MM; Harmsen WS; Therneau TM; Lee HC; Ryoo BY; Bampoh S; Valles KA; Mady M; Missula VR; Prasai K; Roberts LR; Kim KM
    Hepatol Int; 2020 Sep; 14(5):776-787. PubMed ID: 32740886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular carcinoma undergoing sorafenib therapy.
    Saeki I; Yamasaki T; Yamauchi Y; Kawaoka T; Uchikawa S; Hiramatsu A; Aikata H; Kobayashi K; Kondo T; Ogasawara S; Chiba T; Kawano R; Chayama K; Kato N; Takami T
    Cancer Med; 2023 May; 12(9):10625-10635. PubMed ID: 36951579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
    Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK
    Indian J Cancer; 2017; 54(3):526-529. PubMed ID: 29798951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.